



Fig. S1. Patient disposition. Discontinuations are from Baseline to Week 8. The first visit of the first patient was on 28/12/2011, and the last follow-up visit occurred on 17/9/2012.

*Supplementary material to article by D. Roblin et al. "Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from In vitro and Tissue Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b, Randomised, Double-blind, Vehicle-controlled Clinical Trial in Patients with Psoriasis"*